



Gilead's Research Scholars Program: Advancing Science Together in Solid Tumors

Gilead's Research Scholars Program supports innovative research from emerging investigators around the world to advance scientific knowledge in areas of unmet medical needs and improve the lives of patients everywhere.



240+
scholars



\$31 million
awarded



160+
countries

The program is designed to support innovative basic, translational and clinical scientific research related to Oncology Solid Tumors. For the 2022 cycle, the program will focus on Breast Cancer only.

Gilead's Research Scholars Program awards up to two years of financial support to emerging investigators with a strong research track record, who are pursuing an academic career at a research institution in one of the eligible countries at the time of application.

Each award is funded up to \$130,000 USD over two years, paid as annual instalments of \$65,000 USD per year directly to the scholar's institution.

[Click to Download Program Brochure](#)

[Click to Download Program Ad](#)

Visit the [Research Scholars Program in Solid Tumors portal](#) to learn more about the Solid Tumors program, including eligibility and application criteria.

Gilead's Research Scholars Program is committed to building a more diverse and inclusive scientific community. Award selections are made without discrimination based on race, ethnicity, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression.

Each Research Scholars Program is overseen by a Scientific Review Committee composed of distinguished experts in their fields. The Scientific Review Committees oversee each program completely independent from Gilead – and scholars retain their independence as well.

To learn more about the Gilead Research Scholars Program, please visit www.Gilead.com/RSP.

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment.

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2021 Gilead Sciences, Inc. All rights reserved.

Date of Prep: November 2021
Job code: IHQ-UNB-1004